ITGR

Integer Holdings Corporation ITGR delivered adjusted earnings per share (EPS) of $1.60 in the second quarter of 2026, up 3.2% year over year. The figure beat the Zacks Consensus Estimate by 15.9%. The adjustments include expenses related to the amortization of intangible assets and restructuring and restructuring-related charges, among others. GAAP EPS for the quarter was 69 cents, down 33.7 % from the prior-year quarter. Integer Holdings registered revenues of $464.1 million in the second quarter, down 2.6% year over year. However, the figure topped the Zacks Consensus Estimate by 2.2%. Organically, revenues decreased 1.5%. Integer Holdings operates through three product lines — Cardio and Vascular (C&V); Cardiac Rhythm Management & Neuromodulation (CRM&N) and Other Markets. In the second quarter of 2026, the C&V product line generated revenues of $280.3 million, down 2.3% year over year. Organically, sales declined 2.5%. The decrease primarily reflected the previously communicated impact from two new Electrophysiology products. The CRM&N product line reported revenues of $173.7 million, up 1% year over year. Organic sales also increased 1%. Growth in the product line was partially offset by the previously communicated impact from one new Neuromodulation product. Revenues from Other Markets totaled $10.1 million, down 42.8% from $17.6 million in the prior-year quarter. Organically, sales declined 13.5%. The sharp reported decrease primarily reflected Integer Holdings’ strategic exit from the Portable Medical business. Integer Holdings generated a gross profit of $112.9 million in the second quarter, down 12.6% year over year. The gross margin in the reported quarter contracted about 280 basis points (bps) to 24.3% from 27.1% in the prior-year period. Selling, general and administrative expenses were $57.7 million, up 9% year over year. Research, development and engineering costs were $11.3 million in the quarter, down 20.8% year over year. Total operating expenses of $78.4 million increased 12.3% year over year. Adjusted operating profit totaled $73 million, reflecting a decline of 10.2% from the prior-year quarter. Adjusted operating margin in the second quarter contracted about 130 bps to 15.7% from 17.1% a year ago. Integer Holdings exited the second quarter of 2026 with cash and cash equivalents of $21.4 million compared with $8.1 million at the first-quarter end. Total debt (including the current portion) at the end of second-quarter 2026 was $1.24 billion, down from $1.25 billion at the end of the first quarter. Cumulative cash flow from operating activities at the end of second-quarter 2026 was $84.4 million compared with $75.1 million a year ago. Integer Holdings Corporation price-consensus-eps-surprise-chart | Integer Holdings Corporation Quote Integer Holdings and KKR separately announced a definitive agreement under which an affiliate of KKR-managed investment funds will acquire all outstanding Integer shares for $127 per share in cash. The transaction carries an enterprise value of $5.7 billion. Given the pending transaction, Integer Holdings withdrew its previously issued financial outlook. The company also canceled its previously scheduled second-quarter earnings conference call and webcast. Integer Holdings exited the second quarter of 2026 with a mixed performance. Revenues declined year over year, reflecting continued pressure from previously communicated product-related headwinds and the strategic exit from Portable Medical. However, adjusted EPS increased 3.2%, supported by a relatively stable adjusted net income despite the softer top line. On the product-line front, performance remained uneven. Cardio & Vascular sales declined as two new Electrophysiology products continued to weigh on results, while Cardiac Rhythm Management & Neuromodulation posted modest growth despite the impact from one new Neuromodulation product. Profitability also remained under pressure, with adjusted operating income declining 10.2% and gross margin contracting year over year. Still, operating cash flow for the first six months improved to $84.4 million from $75.1 million a year ago. The company withdrew its previously issued 2026 financial outlook in light of the pending acquisition. Integer Holdings and KKR announced a definitive agreement under which an affiliate of KKR-managed investment funds will acquire all outstanding shares of ITGR for $127 per share in cash, valuing the transaction at an enterprise value of $5.7 billion.The transaction is expected to close by the end of 2026. Integer Holdings currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are McKesson MCK, Phibro Animal Health PAHC andCardinal Health CAH. McKesson carries a Zacks Rank #2 (Buy) at present and has an estimated long-term growth rate of 13.7%. MCK’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.09%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. McKessonshares have gained 8.8% against the industry’s 12.7% decline in the year-to-date period. Phibro Animal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21.5%. PAHC’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 16.25%. Phibro Animal Health stock has climbed 44.2% against the industry’s 17.1% decline in the year-to-date period. Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%. Cardinal Health’s shares have lost 2.6% compared with the industry’s 3.1% decline in the year-to-date period. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report McKesson Corporation (MCK) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Integer Holdings (ITGR) has moved into the spotlight after reporting second quarter 2026 earnings alongside a pending all cash acquisition by KKR. Both updates give you fresh information to assess the stock. See our latest analysis for Integer Holdings. Integer Holdings shares have reacted sharply to the proposed US$127 per share cash offer, with a 7 day share price return of 23.98% and a 90 day share price return of 44.22%, while the 5 year total shareholder return of 38.00% highlights a more moderate long term outcome. If the KKR deal has you thinking about what else might be on the move, this is a good moment to broaden your search and check out 19 top founder-led companies Integer Holdings now sits between a premium take private offer and a business that just posted mixed quarterly results. The real issue is whether the current price already captures that quality and deal risk. On Simply Wall St's numbers, Integer Holdings trades on a P/E of 29.8x, which sits between a peer average of 83.2x and an estimated fair P/E of 23.8x, and close to the wider US Medical Equipment industry at 29x. The P/E ratio compares the current share price to earnings per share and is a common way to see how much investors are paying for each dollar of profit. For a medical device contract manufacturer like Integer Holdings, it reflects how the market weighs its earnings profile, growth record and acquisition interest. The company has high quality earnings, profit growth of 80.9% over the past year against a 5 year earnings growth rate of 7.8% per year, and a current net profit margin of 7.6% versus 4.5% last year. Set against this, Return on Equity of 8.4% is considered low, forecast earnings and revenue growth are both described as slower than the broader US market, and the DCF work suggests the $124.45 share price sits 22.3% below an estimated future cash flow value of $160.21. Compared with peers, the 29.8x P/E is described as good value relative to a peer average of 83.2x, yet expensive versus the US Medical Equipment industry average of 29x and above the estimated fair P/E of 23.8x that the fair ratio work points to as a level the market could move towards if sentiment cools. Explore the SWS fair ratio for Integer Holdings Result: Price-to-Earnings of 29.8x (ABOUT RIGHT) However, Integer Holdings still faces deal risk if the KKR transaction falls through, and its slower projected earnings and revenue growth could pressure that 29.8x P/E. Find out about the key risks to this Integer Holdings narrative. The P/E story suggests Integer Holdings might be slightly ahead of itself, yet the SWS DCF model points a different way. On those cash flow assumptions, the stock at $124.45 sits about 22.3% below an estimated value of $160.21. That frames it as undervalued. Which signal appears more reliable to you? Look into how the SWS DCF model arrives at its fair value. Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Integer Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 53 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. The mixed signals around Integer Holdings can feel unclear. Take a moment to review the numbers yourself and see how the story fits your own risk and reward preferences, starting with the 3 key rewards and 1 important warning sign. Do not stop with Integer Holdings. Use this moment to refresh your watchlist with fresh investment ideas that match the kind of risk and return profile you prefer. Spot potential bargains early and scan for companies that look underpriced on quality and fundamentals through the 53 high quality undervalued stocks Build a steadier income stream and hunt for reliable payers with the 7 dividend fortresses Prioritise resilience first and focus on companies with stronger balance sheets and fundamentals using the solid balance sheet and fundamentals stocks screener (46 results) This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ITGR. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - specialty industry, including Integer Holdings (NYSE:ITGR) and its peers. The medical devices industry operates a business model that balances steady demand with significant investments in innovation and regulatory compliance. The industry benefits from recurring revenue streams tied to consumables, maintenance services, and incremental upgrades to the latest technologies, although specialty devices are more niche. The capital-intensive nature of product development, coupled with lengthy regulatory pathways and the need for clinical validation, can weigh on profitability and timelines. In addition, there are constant pricing pressures from healthcare systems and insurers maximizing cost efficiency. Over the next several years, one tailwind is demographic–aging populations means rising chronic disease rates that drive greater demand for medical interventions and monitoring solutions. Advances in digital health, such as remote patient monitoring and smart devices, are also expected to unlock new demand by shortening upgrade cycles. On the other hand, the industry faces headwinds from pricing and reimbursement pressures as healthcare providers increasingly adopt value-based care models. Additionally, the integration of cybersecurity for connected devices adds further risk and complexity for device manufacturers. The 7 medical devices & supplies - specialty stocks we track reported a strong Q1. As a group, revenues beat analysts’ consensus estimates by 5.3%. Thankfully, share prices of the companies have been resilient as they are up 7.4% on average since the latest earnings results. With its name reflecting the mathematical term for "whole" or "complete," Integer Holdings (NYSE:ITGR) is a medical device outsource manufacturer that produces components and systems for cardiac, vascular, neurological, and other medical applications. Integer Holdings reported revenues of $439.6 million, flat year on year. This print exceeded analysts’ expectations by 3.1%. Despite the top-line beat, it was still a slower quarter for the company with a significant miss of analysts’ full-year EPS and revenue guidance. “First quarter financial performance was in line with our outlook and primarily reflected the previously communicated headwinds associated with the three new products,” said Payman Khales, Integer’s President and CEO. Integer Holdings delivered the slowest revenue growth of the whole group. Interestingly, the stock is up 15.2% since reporting and currently trades at $96.38. Read our full report on Integer Holdings here, it’s free. With over 2.5 million implants performed worldwide, STAAR Surgical (NASDAQ:STAA) designs and manufactures implantable lenses that correct vision problems without removing the eye's natural lens. STAAR Surgical reported revenues of $93.52 million, up 120% year on year, outperforming analysts’ expectations by 20.8%. The business had an incredible quarter with a beat of analysts’ EPS estimates. STAAR Surgical scored the biggest analyst estimate beat and fastest revenue growth among its peers. Although it had a fine quarter compared to its peers, the market seems unhappy with the results as the stock is down 5.5% since reporting. It currently trades at $27.79. Is now the time to buy STAAR Surgical? Access our full analysis of the earnings results here, it’s free. Offering an alternative for the millions who struggle with traditional CPAP machines, Inspire Medical Systems (NYSE:INSP) develops and sells an implantable neurostimulation device that treats obstructive sleep apnea by stimulating nerves to keep airways open during sleep. Inspire Medical Systems reported revenues of $204.6 million, up 1.6% year on year, exceeding analysts’ expectations by 1.9%. Still, it was a slower quarter as it posted full-year revenue and EPS guidance missing analysts' estimates. Inspire Medical Systems delivered the weakest performance against analyst estimates and weakest full-year guidance update in the group. As expected, the stock is down 6.3% since the results and currently trades at $51.36. Read our full analysis of Inspire Medical Systems’s results here. With a focus on helping patients regain or maintain their natural motion, Enovis (NYSE:ENOV) develops and manufactures medical devices for orthopedic care, from injury prevention and pain management to joint replacement and rehabilitation. Enovis reported revenues of $589.2 million, up 5.4% year on year. This number surpassed analysts’ expectations by 3.1%. Taking a step back, it was a satisfactory quarter as it also recorded a beat of analysts’ EPS estimates but full-year revenue guidance meeting analysts’ expectations. The stock is up 7.6% since reporting and currently trades at $26.74. Read our full, actionable report on Enovis here, it’s free. With operations spanning 64 countries and a portfolio of over 10 new products launched in 2023 alone, Globus Medical (NYSE:GMED) develops and sells implantable devices, surgical instruments, and technology solutions for spine, orthopedic, and neurosurgical procedures. Globus Medical reported revenues of $759.9 million, up 27% year on year. This result topped analysts’ expectations by 2.7%. Overall, it was a very strong quarter as it also logged an impressive beat of analysts’ full-year EPS guidance estimates. The stock is down 7.1% since reporting and currently trades at $79.05. Read our full, actionable report on Globus Medical here, it’s free. Over the past year, investors have been forced to repeatedly answer the same question: what is the market’s biggest risk? The answer has changed several times, and each shift has reshaped market leadership. Late in 2025 and early 2026, artificial intelligence became the market’s primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products. By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market’s dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals. Want to invest in winners with rock-solid fundamentals? Check out our Strong Momentum Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.

It has been about a month since the last earnings report for Integra LifeSciences (IART). Shares have added about 15% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Integra due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important catalysts. Integra LifeSciences Holdings Corporation (IART) delivered adjusted earnings per share (EPS) of 54 cents for the first quarter of 2026, which beat the Zacks Consensus Estimate by 32.8%. The metric increased 31.7% year over year. GAAP loss per share was 6 cents in the quarter compared with the year-ago period’s loss of 33 cents. Total revenues in the first quarter rose 2.4% year over year to $391.9 million. The metric topped the Zacks Consensus Estimate by 2.7%. Organically, revenues rose 1.3% year over year. For full-year 2026, the company expects revenues to be in the range of $1.66-$1.70 billion, representing reported growth of 1.6% to 4.1%. The Zacks Consensus Estimate is pegged at $1.67 billion, indicating 2.2% year-over-year growth. Meanwhile, the company updated its expected adjusted EPS to a range of $2.40-$2.50. The Zacks Consensus Estimate for the metric is pegged at $2.42 per share. For the second quarter of 2026, Integra expects reported revenues in the range of $410-$425 million. The Zacks Consensus Estimate is pegged at $417.5 million. Adjusted EPS is expected to be in the range of 44-52 cents. The Zacks Consensus Estimate for the metric is pegged at 49 cents per share. In the past month, investors have witnessed a downward trend in estimates review. The consensus estimate has shifted -10.74% due to these changes. Currently, Integra has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. However, the stock has a grade of B on the value side, putting it in the top 40% for value investors. Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Integra has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months. Integra belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, Integer (ITGR), has gained 5.3% over the past month. More than a month has passed since the company reported results for the quarter ended March 2026. Integer reported revenues of $439.58 million in the last reported quarter, representing a year-over-year change of +0.5%. EPS of $1.20 for the same period compares with $1.31 a year ago. For the current quarter, Integer is expected to post earnings of $1.38 per share, indicating a change of -11% from the year-ago quarter. The Zacks Consensus Estimate has changed -4.2% over the last 30 days. Integer has a Zacks Rank #4 (Sell) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Integra LifeSciences Holdings Corporation (IART) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Integer Holdings has had an impressive run over the past six months as its shares have beaten the S&P 500 by 15%. The stock now trades at $85.04, marking a 25% gain. This performance may have investors wondering how to approach the situation. Is there a buying opportunity in Integer Holdings, or does it present a risk to your portfolio? Dive into our full research report to see our analyst team’s opinion, it’s free. Despite the momentum, we're swiping left on Integer Holdings for now. Here are three reasons why ITGR doesn't excite us and a stock we'd rather own. Larger companies benefit from economies of scale, where fixed costs like infrastructure, technology, and administration are spread over a higher volume of goods or services, reducing the cost per unit. Scale can also lead to bargaining power with suppliers, greater brand recognition, and more investment firepower. A virtuous cycle can ensue if a scaled company plays its cards right. With just $1.86 billion in revenue over the past 12 months, Integer Holdings is a small company in an industry where scale matters. This makes it difficult to build trust with customers because healthcare is heavily regulated, complex, and resource-intensive. Forecasted revenues by Wall Street analysts signal a company’s potential. Predictions may not always be accurate, but accelerating growth typically boosts valuation multiples and stock prices while slowing growth does the opposite. Over the next 12 months, sell-side analysts expect Integer Holdings’s revenue to stall, a deceleration versus its 12.4% annualized growth for the past five years. This projection doesn't excite us and indicates its products and services will see some demand headwinds. Growth gives us insight into a company’s long-term potential, but how capital-efficient was that growth? Enter ROIC, a metric showing how much operating profit a company generates relative to the money it has raised (debt and equity). Integer Holdings historically did a mediocre job investing in profitable growth initiatives. Its five-year average ROIC was 5.4%, somewhat low compared to the best healthcare companies that consistently pump out 20%+. Integer Holdings’s business quality ultimately falls short of our standards. With its shares topping the market in recent months, the stock trades at 13.3× forward P/E (or $85.04 per share). While this valuation is reasonable, we don’t really see a big opportunity at the moment. We're fairly confident there are better investments elsewhere. We’d recommend looking at the Amazon and PayPal of Latin America. WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses. But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE. Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

Integer reported Q1 results roughly in line with prior guidance but lowered full‑year guidance, now forecasting reported sales of $1.805–$1.835 billion and adjusted EPS of $5.83–$6.40 with organic sales expected flat to down ~1%. The board has initiated a strategic review amid intensified interest in the company, though management says there is no timeline and no assurance the review will result in a transaction. Management highlighted margin pressure from lower fixed‑cost absorption and electrophysiology (PFA) forecast volatility, is implementing additional near‑term cost actions, and has continued share repurchases (~$100M completed) with net leverage at 3.2x. Interested in Integer Holdings Corporation? Here are five stocks we like better. After blowout earnings, Integer may be headed to new highs Integer (NYSE:ITGR) reported first-quarter 2026 results that management said were in line with the outlook it provided in February, while also lowering its full-year forecast to reflect updated customer forecasts and additional risk adjustments across its portfolio. The company also disclosed that its board has initiated a strategic review process. President and CEO Payman Khales said first-quarter sales rose 0.5% year over year on a reported basis and increased 1.3% organically. Khales attributed the quarter’s sales performance primarily to “the decline associated with the three new products” previously discussed by the company, along with the impact of exiting the Portable Medical business. → Corning Beats Q1 Estimates but Drops 9% on Guidance Miss Diron Smith, executive vice president and CFO, said first-quarter sales totaled $440 million. The company posted adjusted EBITDA of $85 million, down $7 million, and adjusted operating margin contracted 230 basis points to 13.9%. Adjusted net income was $41 million, down 10% year over year, and adjusted EPS was $1.20, down 8%. Khales said adjusted EPS benefited from lower interest expense, which was offset by the decline in adjusted operating income. Smith added that interest expense was $4 million lower than the prior year, contributing $0.10 per share, reflecting savings from a convertible debt offering completed in March 2025. → Meta Posted Its Best Sales Growth Since 2021—So Why Did Shares Fall? Smith said Cardio & Vascular (C&V) sales increased 1% to $262 million in the quarter, “which primarily reflected lower electrophysiology sales from the two new products we have previously discussed.” On a trailing four-quarter basis, C&V sales increased 13% to $1.11 billion, driven by electrophysiology growth, acquisitions, and strong demand in neurovascular. Cardiac Rhythm Management & Neuromodulation (CRM&N) sales increased 5% to $168 million. Smith said CRM growth was partially offset by the previously communicated headwind in Neuromodulation. On a trailing four-quarter basis, CRM&N sales increased 2% to $677 million, with CRM growth partially offset by “the planned decline related to an early spinal cord stimulation customer.” → Is Oracle Undervalued as Cloud Growth Accelerates? In response to a question on CRM and neuromodulation, Khales said the CRM business “is performing well” and came “slightly ahead of expectations” in the first quarter. He reiterated that neuromodulation is being pressured in 2026 by “a reduction of the one product,” but added that the company still expects its neuromodulation portfolio—particularly emerging customers with PMA products—to contribute to growth in the coming years. Smith said the year-over-year decline in profitability was driven primarily by lower fixed-cost absorption, which weighed on gross margin performance. Operating expenses were flat versus the prior year, including lower SG&A and a slight increase in R&D and engineering expenses due to the timing of milestone achievements for customer-funded development work. The adjusted effective tax rate was 19% compared with 17.4% in the prior-year quarter, while the company maintained its expectation for a full-year adjusted tax rate of 16% to 18%. Smith also highlighted continued share repurchases. After completing a $50 million repurchase of approximately 700,000 shares in the fourth quarter of 2025, Integer completed an additional $50 million repurchase of approximately 600,000 shares in the first quarter of 2026. The lower share count contributed $0.02 to adjusted EPS, Smith said. Cash flow from operations was $25 million, down $6 million, and capital expenditures were $24 million, resulting in free cash flow of $1 million. Net total debt ended the quarter at $1.264 billion, up $74 million, primarily due to the quarter’s $50 million share repurchase. Net leverage was 3.2x trailing four-quarter adjusted EBITDA, within the company’s strategic target range of 2.5x to 3.5x. Management updated its 2026 outlook ranges to reflect “recent customer forecast updates and further risk adjustments,” Khales said. The company now expects reported sales to be down 1% to 3% year over year, and organic sales to be flat to down 1%. Khales said Integer continues to expect a 3% to 4% headwind from the three new products, and that “the outlook for these three products has not changed.” However, he said recent customer forecast updates “primarily affect the second-half outlook for a few products in electrophysiology,” and that the company further risk-adjusted its outlook “to minimize the risk of additional forecast erosion.” Smith detailed the updated full-year 2026 guidance: Reported sales: $1.805 billion to $1.835 billion (down 1% to 3%) Adjusted EBITDA: $375 million to $399 million (down 1% to 7%) Adjusted operating income: $285 million to $305 million (down 5% to 11%) Adjusted net income: $200 million to $220 million (down 3% to 11%) Adjusted EPS: $5.83 to $6.40 (flat to down 9%) Within the sales outlook, Smith said Integer expects organic growth excluding the three new products to be about 3% to 4%, down from a prior expectation of 4% to 6%, reflecting forecast changes and additional risk adjustments. He also said the company expects an inorganic decline of about 1%, reflecting the completed Portable Medical exit, slightly offset by acquisitions and foreign exchange. By product line, Smith said Integer now expects C&V sales to be flat to down low single digits, revised from prior expectations of flat to up low single digits, due to the electrophysiology forecast updates. CRM&N guidance remained flat to up low single digits, including the previously communicated neuromodulation headwind. Management discussed the electrophysiology market environment and forecast volatility tied to rapid adoption of pulsed field ablation (PFA) technologies. Khales said OEMs had sought to maintain availability across multiple products to prepare for adoption scenarios, contributing to variability in forecast and ordering patterns. He said Integer is now “entering a period of normalization,” and that certain customers have adjusted forecasts for a few products, which Integer expects to be “short-term, primarily impacting the second half of 2026.” Khales emphasized the reductions were “not due to insourcing or a shift to alternative suppliers.” On the earnings call, Khales told analysts he did not believe the forecast changes reflected a broad market deterioration, describing the EP market as “normalizing” and expecting EP market growth “in the range of mid-teens to high teens in 2026,” versus north of 20% last year. He also said the impacted products were used in ablation procedures independent of technology, and described the issue as customers adjusting production plans as visibility improves. In another exchange, he said procedure volume growth was expected to be “close to the high single digits to low double digits,” citing roughly 10% to 12% as the company’s view. Smith said the company anticipates “further margin pressure” from the lower sales outlook and is taking “additional near-term cost actions” included in the revised forecast. In Q&A, Smith said Integer was looking to be “more aggressive on the cost actions and the disciplined cost management,” while not making structural changes that would damage its ability to return to market growth and its targeted above-market growth profile. Khales also addressed a separate announcement that the board has initiated a strategic review. He said the board and management remain confident in the company’s standalone strategy and long-term objectives, but noted that “interest in Integer has historically been strong and has intensified in recent months.” Given the heightened interest, he said the board believes “now is the right time to consider all opportunities to maximize shareholder value,” which may include continuing to execute the standalone strategy. Khales said there is “no deadline or definitive timeline” for the review and “no assurance that the review will result in any transaction or other outcome.” Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance. Integer's product portfolio is organized into two core segments: Advanced Delivery and MedTech. The article "Integer Q1 Earnings Call Highlights" was originally published by MarketBeat.

Performance in Q1 was primarily impacted by the previously identified decline in three specific products and the strategic exit from the portable medical market. Management attributes the updated 2026 outlook to recent customer forecast reductions in the electrophysiology (EP) market, which they characterize as a period of 'normalization' following rapid Pulsed Field Ablation (PFA) adoption. The EP forecast adjustments are described as short-term inventory and production plan recalibrations by OEMs rather than a loss of market share, in-sourcing, or shifts to competitors. Beyond specific EP updates, management has applied broader risk adjustments across the entire portfolio to minimize the impact of potential further forecast erosion during this volatile period. Operating margin contraction of 230 basis points in Q1 was driven by lower fixed cost absorption resulting from the lower sales volume. Management emphasizes that 2026 is a transition year, with the underlying medical device markets remaining strong and the company's long-term strategy unchanged. The company expects to return to organic sales growth at 200 basis points above the market rate in 2027, supported by a robust new product introduction (NPI) pipeline. Guidance for the remainder of 2026 assumes organic sales will return to market growth levels by the fourth quarter, despite a 5% headwind from fewer production days. Management is implementing additional near-term cost reduction actions to mitigate bottom-line pressure without compromising the ability to service 2027 growth commitments. The 2027 growth algorithm assumes the EP market will stabilize in the mid-to-high teens growth range, with Integer's portfolio contributing significantly to above-market performance. Capital expenditure is projected to remain at 5% to 6% of sales to support long-term growth initiatives and high-growth markets like structural heart and neurovascular. The Board of Directors has initiated a formal strategic review to evaluate opportunities to maximize shareholder value, citing 'heightened interest' in the company in recent months. Management clarified that the strategic review has no definitive timeline and may result in continuing the current stand-alone strategy. The exit from the portable medical business is now complete, contributing to a 1% inorganic decline in the 2026 reported sales outlook. The company completed a $50 million share repurchase in Q1, following a similar $50 million repurchase in Q4 2025, reflecting a commitment to capital allocation discipline. Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management clarified the new adjustments are unrelated to the two PFA products discussed previously and involve accessory products used across various ablation technologies. The reductions are viewed as a 'one-time' adjustment to order patterns as customers gain better visibility into post-PFA-disruption market needs. The review was triggered by intensified external interest in recent months, despite management's continued confidence in the stand-alone strategy. The Board aims to fulfill its fiduciary duty by exploring all options to maximize value, though no specific transaction is guaranteed. Confidence in 2027 is driven by the exit rate expected in Q4 2026 and a strong pipeline of new product launches across all growth markets. The 2027 outlook does not rely on any contribution from the two specific PFA products that faced adoption challenges. Management views the impact of rising fuel prices and Middle East conflict as manageable and not material to the current outlook, specifically noting that fuel price exposure is limited because most customers handle their own logistics and pick up products directly from manufacturing facilities. Exposure to logistics inflation is limited because most customers manage their own product pickups from Integer facilities. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Integer Holdings Corporation ITGR delivered adjusted earnings per share (EPS) of $1.20 in the first quarter of 2026, which declined 8.4% year over year. The figure missed the Zacks Consensus Estimate by 0.8%. The adjustments include expenses related to the amortization of intangible assets and restructuring and restructuring-related charges, among others. GAAP EPS for the quarter was 48 cents, up 172.7% from the prior-year quarter. Integer Holdings registered revenues of $439.6 million in the first quarter, up 0.5% year over year. The figure topped the Zacks Consensus Estimate by 3%. Organically, revenues increased 1.3%. Robust sales from the majority of the product lines drove the company’s top line in the reported period. Integer Holdings operates through three product lines — Cardio and Vascular (C&V); Cardiac Rhythm Management & Neuromodulation (CRM&N) and Other Markets. During the fourth quarter of 2025, management began referring to ITGR’s Advanced Surgical, Orthopedics & Portable Medical product line as the Other Markets product line. This was aimed at better capturing the evolving nature of the company’s products and ongoing strategic focus. Per management, the name change has no impact on the financial information previously reported. In the first quarter of 2026, the C&V segment generated revenues of $262 million, reflecting a modest 1% year-over-year increase. Growth in the segment was primarily supported by continued strength in neurovascular and contributions from prior acquisitions. However, performance was partially offset by lower electrophysiology sales, mainly related to previously disclosed headwinds from certain new products. The CRM&N segment reported revenues of $168 million, up 5% year over year. Growth was driven by solid performance in the cardiac rhythm management business, which more than offset ongoing weakness in neuromodulation. The neuromodulation decline was consistent with prior expectations and reflects previously communicated product-related headwinds. Revenues from Other Markets declined year over year, primarily due to the continued impact of Integer Holdings’ strategic exit from the Portable Medical business. This segment remains outside the company’s core growth focus and largely reflects legacy manufacturing service agreements tied to divested operations. Integer Holdings Corporation price-consensus-eps-surprise-chart | Integer Holdings Corporation Quote Integer Holdings generated a gross profit of $109.6 million in the first quarter, down 8.9% year over year. The gross margin in the reported quarter contracted 260 basis points (bps) to 24.9%. We projected 26.4% of gross margin for the first quarter. Selling, general and administrative expenses were $58.7 million, up 14.8% year over year. Research, development and engineering costs were $16.2 million in the quarter, up 14.4% year over year. Total operating expenses of $77.7 million increased 9.8% year over year. Adjusted operating profit totaled $61.1 million, reflecting a decline of 13.9% from the prior-year quarter. Adjusted operating margin in the first quarter contracted 230 bps to 13.9%. Integer Holdings exited the first quarter of 2026 with cash and cash equivalents of $8.1 million compared with $17.2 million at the fourth-quarter end. Total debt (including the current portion) at the end of first-quarter 2026 was $1.25 billion, up from $1.19 billion at the end of the fourth quarter. Net cash flow from operating activities at the end of first-quarter 2026 was $24.7 million compared with $31.3 million a year ago. Integer Holdings updated its 2026 outlook. For 2026, the company now expects revenues in the range of $1.805-$1.835 billion, implying a decline of 1-3% on a reported basis from the 2025 level. On an organic basis, sales are projected to be flat to down 1%. The Zacks Consensus Estimate is pegged at $1.85 billion. Adjusted EPS are now expected in the band of $5.83-$6.40, implying a range from flat to a 9% decline year over year. The Zacks Consensus Estimate is pegged at $6.47 per share. Integer Holdings exited the first quarter of 2026 with mixed results. The modest top-line growth, coupled with a contraction in adjusted operating margin due to lower fixed-cost absorption, reflects ongoing near-term pressures on operating leverage. On the segmental front, performance remained uneven. The Cardio & Vascular business delivered modest growth, though electrophysiology sales were impacted by previously communicated headwinds from certain new products. Meanwhile, strength in Cardiac Rhythm Management supported the CRM&N segment, partially offset by continued softness in neuromodulation. The company also maintained disciplined cost control and benefited from lower interest expense, which provided some support to earnings despite margin pressures. Management’s revised 2026 outlook remains a key overhang. The company now expects revenues to decline 1-3% year over year, indicating customer forecast reductions and headwinds from certain new products. While the underlying business, excluding these headwinds, is still expected to grow in the low to mid-single digits, 2026 is shaping up to be a transition year, with growth expected to normalize exiting the year and reaccelerate in 2027. However, shares of ITGR gained 5.8% in yesterday’s trading session. ITGR stock has gained 12.9% in the year-to-date period against the industry’s 17.4% decline. However, the S&P 500 Index has increased 6.2% during the same time frame. Image Source: Zacks Investment Research Integer Holdings currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space that are expected to report earnings soon are DexCom, Inc. DXCM, Encompass Health Corporation EHC and The Cooper Companies, Inc. COO. The Zacks Consensus Estimate for DexCom’s first-quarter 2026 adjusted EPS is currently pegged at 47 cents. The consensus estimate for revenues is pegged at $1.18 billion. DXCM currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. DexCom has an estimated long-term growth rate of 20.6%. DXCM’s earnings yield of 4.1% compares favorably with the industry’s negative yield. Encompass Health currently has a Zacks Rank #2. The Zacks Consensus Estimate for its first-quarter 2026 adjusted EPS is currently pegged at $1.51. The same for revenues is pegged at $1.57 billion. Encompass Health has an estimated long-term growth rate of 8.8%. EHC’s earnings yield of 5.9% compares favorably with the industry’s 5.6%. Cooper Companies currently carries a Zacks Rank #2. The Zacks Consensus Estimate for its second-quarter fiscal 2026 adjusted EPS is currently pegged at $1.10. The same for its revenues is pegged at $1.05 billion. Cooper Companies has an estimated long-term growth rate of 8.4%. COO’s earnings yield of 7.2% compares favorably with the industry’s 6.1%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report The Cooper Companies, Inc. (COO) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Encompass Health Corporation (EHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Integer (ITGR) came out with quarterly earnings of $1.2 per share, missing the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $1.31 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -0.66%. A quarter ago, it was expected that this medical device outsource manufacturer would post earnings of $1.7 per share when it actually produced earnings of $1.76, delivering a surprise of +3.53%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Integer, which belongs to the Zacks Medical - Instruments industry, posted revenues of $439.58 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 3.04%. This compares to year-ago revenues of $437.39 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Integer shares have added about 6.7% since the beginning of the year versus the S&P 500's gain of 4.2%. While Integer has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Integer was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.58 on $462.92 million in revenues for the coming quarter and $6.47 on $1.85 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the bottom 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Si-Bone (SIBN), has yet to report results for the quarter ended March 2026. The results are expected to be released on May 11. This medical device maker is expected to post quarterly loss of $0.17 per share in its upcoming report, which represents a year-over-year change of -13.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Si-Bone's revenues are expected to be $51.33 million, up 8.5% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report SiBone (SIBN) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research